Literature DB >> 20449611

Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma.

Yuki Fujiwara1, Hiroaki Shiba, Kenei Furukawa, Tomonori Iida, Taro Sakamoto, Takeshi Gocho, Shigeki Wakiyama, Shoichi Hirohara, Yuichi Ishida, Takeyuki Misawa, Toya Ohashi, Katsuhiko Yanaga.   

Abstract

BACKGROUND: In spite of improvements in surgical management, hepatocellular carcinoma (HCC) still recurs after operation in 60-70% of patients. Therefore, we investigated the relation between perioperative change in white blood cell count (WBC) and tumor recurrence as well as survival in patients with HCC after hepatic resection.
METHODS: Subjects were 53 patients who underwent elective hepatic resection for HCC. We retrospectively examined the relation between perioperative change in WBC and recurrence of HCC as well as overall survival.
RESULTS: Advanced tumor stage and increasing of WBC on postoperative day (POD) 1 were positively associated with worse disease-free survival rate on both univariate and multivariate analysis (P < 0.05). Advanced tumor stage, increasing of WBC on POD 1, and blood transfusion were positively associated with worse overall survival rate on univariate analysis (P < 0.05), while change in WBC was the only independent factor on multivariate analysis (P < 0.05).
CONCLUSIONS: Perioperative change in WBC after elective hepatic resection for HCC is positively associated with recurrence and worse survival.

Entities:  

Mesh:

Year:  2010        PMID: 20449611     DOI: 10.1007/s00534-010-0290-4

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  2 in total

1.  Preoperative peripheral blood neutrophil count predicts long-term outcomes following hepatic resection for colorectal liver metastases.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yuki Fujiwara; Kenei Furukawa; Tomonori Iida; Masahisa Ohkuma; Masaichi Ogawa; Yuichi Ishida; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

2.  Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis.

Authors:  Fumihiro Hirata; Kohei Ishiyama; Yuka Tanaka; Tsuyoshi Kobayashi; Masakazu Hashimoto; Yoshihiro Saeki; Nobuki Ishida; Kazuhiro Taguchi; Junko Tanaka; Koji Arihiro; Hideki Ohdan
Journal:  Ann Gastroenterol Surg       Date:  2018-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.